bjgabrielsen

Lessons From a Live Oak Tree.

This morning I experienced a brief but annoying episode of a recurrent medical issue and potentially a new one. My initial reaction was tension mixed with a little “worry” and “what if”. I have been down that same road before. Almost immediately, God’s Word from James 1:6-7 came to me. “For the one who doubts more »

Adding Provenge to Xtandi or Zytiga Reduces Risk of Death by 45% in Metastatic Hormone Resistant Prostate Cancer

Data from more than 6,000 Medicare patients showed that adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extended the lives of men with metastatic hormone-resistant prostate cancer (mCRPC). The findings were presented in a poster at the recent American Society of Clinical Oncology (ASCO) more »

Put Your Hope in God

Several years ago, I experienced an annoying side effect which had arisen related to earlier prostate cancer therapy. The side effect had been “cured” by a specific series of treatments but now it had reared its troublesome head again. One recent Sunday, it was especially troublesome. There are potential treatments for this condition but my more »

A Life of Peace

This website usually focuses exclusively on prostate cancer but this particular post could apply to the current worldwide coronavirus pandemic as well. Right now we as a nation and many of us as individuals may have a potential medical problem that has our stomach in knots with persistent worry. For most of us, it is more »

Molecular Imaging PSMA PET/CT Could Transform Management of People with Aggressive Cancer

Upon recent discussions with my urologist and oncologist, they both informed me that the following is a highly significant development in imaging of prostate cancer. A medical imaging technique, known as PSMA PET/CT, that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for more »

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer in Men with BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration (hormone)-resistant prostate cancer (mCRPC) and BRCA mutations. Clovis submitted its application to the FDA in November, 2019. The priority review status will shorten Rubraca’s regulatory review for this more »

A Clinical Trial for Men With Low – Intermediate Risk Prostate Cancer Considering Radiation Therapy.

The National Cancer Institute (NCI) is sponsoring a clinical trial at many locations comparing two types of radiation therapy, stereotactic body radiation therapy (SBRT) with intensity-modulated radiation therapy (IMRT). The former is administered in less than two weeks while the latter is given in five weeks. The aim of the trial is to compare cure more »

Prostate Cancer Foundation (PCF) 2019 Guide

Every year, the PCF publishes an electronic guide providing information on all aspects of prostate cancer. The chapters covered are as follows. General information including diagnosis, symptoms, risk factors, and medical basics. Information for the newly diagnosed, including detection, diagnosis and treatment selection. Treatment options for localized or locally advanced prostate cancer. These include active more »

Pyl Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions

Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from the Phase 3 CONDOR clinical trial. “There is a need for improved diagnostics for prostate cancer to replace conventional imaging tests that have limited performance characteristics, especially in more »

Higher Radiation Therapy Doses Over Shorter Time Show No Added Side Effects in Men with Prostate Cancer.

Delivering higher doses of radiation therapy over a shorter time period — an approach called stereotactic body radiation therapy (SBRT) — does not worsen side effects in men with localized prostate cancer, compared to conventional radiation therapy, a Phase 3 trial shows. The study also suggests that SBRT delivered through the CyberKnife System is less more »

From Prostvac to Fear Then to Faith

As many of you readers know, I have earlystage, asymptomatic but advanced prostate cancer. After treatment with Provenge, I was informed (perhaps divinely through a former colleague) of a National Cancer Institute (NCI) clinical trial currently recruiting patients like myself. The protocol involves treatment with the vaccine Prostvac and the antibody therapy, Opdivo. I had written more »

PSMA PET-CT Offers Best Detection Rates in Recurrent Prostate Cancer.

In a recent study, investigators reported the findings of a clinical trial designed to compare the rates for detecting recurrent cancer sites using the prostate-specific membrane antigen (PSMA) PET-CT imaging agent (68Ga-PSMA-11) to those of 18F-fluciclovine in a group of men with recurrent prostate cancer who had already undergone prostatectomy and had very low levels more »

FDA Approves Erleada to Treat Metastatic Castration-sensitive Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic, castration (hormone)-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation (hormonal) therapy (ADT). The decision is based on the double-blind TITAN Phase 3 trial (NCT02489318), as it showed that adding Janssen’s Erleada to more »